⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Towards A Better Paradigm for Head and Neck Cancer Treatment Applying Artificial Intelligence. HNC-TACTIC.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Towards A Better Paradigm for Head and Neck Cancer Treatment Applying Artificial Intelligence. HNC-TACTIC.

Official Title: Towards A Better Paradigm for Head and Neck Cancer Treatment Applying Artificial Intelligence: an International Cohort Study of Electronic Health Records. HNC-TACTIC.

Study ID: NCT05117775

Study Description

Brief Summary: This will be an international, multicenter, retrospective, observational, and data-driven study using secondary data captured in EHRs. The extraction of the data captured in the EHRs will be performed with SAVANA's EHRead®, an innovative data-driven system based on Natural Language Processing (NLP) and machine learning. For all patients, the Index Date is defined as the timepoint within the study period when they fulfill ALL inclusion criteria and no exclusion criteria. Follow-up comprises the period between Index Date and the last EHR available within the study period. Additional variable-specific time windows may be considered to optimize data collection.

Detailed Description: The present study aims to describe the clinical characteristics of patients with HNSCC in a real-world setting by analyzing readily available information in the Electronic Health Records (EHRs). This study will gain a deep insight of the clinical characteristics and real-world outcomes of patients with all stages (early, locally advanced, and metastatic) of HNSCC. It will focus on developing two predictive models to apply in the clinical setting, one for electing patients with high-risk of recurrence after radical treatment, and the second one for selecting recurrent or metastatic patients who could benefit from immunotherapy. To achieve the proposed study objectives we will use SAVANA´s EHRead® (11-15), a technology that applies Natural Language Processing (NLP) (16) and machine learning to extract, organize, and analyze the unstructured clinical information jotted down by health professionals in patients' EHRs. Primary objectives * To develop a predictive model based on dynamic risk stratification (DRS) for the risk of recurrence or disease progression following a primary curative treatment in HNSCC patients with early and locally advanced disease. * To develop a predictive model based on dynamic risk stratification (DRS) aimed at identifying patients' features that predict long-term survival after immunotherapy in recurrent and metastatic HNSCC patients. Secondary objectives * To describe median OS by primary tumor location (oral cavity, oropharynx, larynx, and hypopharynx) in HNSCC patients after stratification for prognostic factors, including tumor stage and treatment. * To describe the demographics, clinical characteristics, and treatment of patients with HNSCC in early and locally advanced stages of the disease. * To describe the patterns of follow-up in patients with HNSCC in early and locally advanced stages of the disease. * Departments in charge * Number of visits * Imaging and anatomopathological tests * Recurrence detected by physical examination. * To evaluate the impact of treatments on patients with locally advanced stages of the disease. * Patients' early and late toxicity to the treatment, comparing between radiotherapy (+/-cisplatin or cetuximab) vs surgery and post-operative r\< radiotherapy (+/- cisplatin). * Healthcare resource utilization (HCRU), including medical visits, diagnostics, and hospitalizations. * To compare OS in locally advanced HNSCC patients (including both HPV+ and HPV- oropharyngeal patients) treated with cisplatin-radiotherapy vs cetuximab-radiotherapy and treated with surgery vs. conservative treatment. * To compare the demographic and clinical characteristics of exceptional responders and poor responders (based on recurrence and long-term survival). This analysis will be performed independently for HPV+ and HPV- oropharyngeal patients.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Savan Research S.L, Madrid, , Spain

Contact Details

Name: John Almeida

Affiliation: University Health Network and Mount Sinai Hospital

Role: STUDY_CHAIR

Name: Sujith Baliaga

Affiliation: Ohio State University

Role: STUDY_CHAIR

Name: David Casadevall

Affiliation: Medsavana S.L

Role: STUDY_CHAIR

Name: Melvin Chua

Affiliation: National Cancer Centre, Singapore

Role: STUDY_CHAIR

Name: Andreas Dietz

Affiliation: University Hospital of Leipzig

Role: STUDY_CHAIR

Name: Robert Ferris

Affiliation: UPMC Hillman Cancer Center

Role: STUDY_CHAIR

Name: Raul Giglio

Affiliation: Hopital Ángel H. Roffo de Buenos Aires

Role: STUDY_CHAIR

Name: Chris Holsinger

Affiliation: Stanford University

Role: STUDY_CHAIR

Name: Kate Hutcheson

Affiliation: M.D. Anderson Cancer Center

Role: STUDY_CHAIR

Name: Husham Menhanna

Affiliation: Institute of Head and Neck Studies and Education (InHANSE)

Role: STUDY_CHAIR

Name: Pablo Parente

Affiliation: Hospital HM Rosaleda

Role: STUDY_CHAIR

Name: Sandro Porceddu

Affiliation: Queensland Institute of Medical Research (QIMR)

Role: STUDY_CHAIR

Name: Miren Taberna

Affiliation: Medsavana S.L

Role: PRINCIPAL_INVESTIGATOR

Name: Christian Simon

Affiliation: CHUV Lausanne

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: